Atlas Trials

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Clinical trial NCT01142388 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT01142388
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Esophageal AdenocarcinomaMetastatic Esophageal Squamous Cell CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaRecurrent Esophageal AdenocarcinomaRecurrent Esophageal CarcinomaRecurrent Esophageal Squamous Cell CarcinomaRecurrent Gastroesophageal Junction AdenocarcinomaStage IV Esophageal Cancer AJCC v7
Start date
2010-09-21
Primary completion
2014-07-15
Enrollment
94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.